DNA vs AMGN

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 23, 2026

DNA

56.3
AI Score
VS
DNA Wins

AMGN

27.2
AI Score

Investment Advisor Scores

DNA

56score
Recommendation
HOLD

AMGN

27score
Recommendation
SELL

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric DNA AMGN Winner
Revenue 39.63M 18.67B AMGN
Net Income -129.30M 4.19B AMGN
Net Margin -326.3% 22.5% AMGN
Operating Income -129.92M 6.18B AMGN
ROE -30.8% 35.9% AMGN
ROA -13.1% 4.4% AMGN
Total Assets 990.05M 95.64B AMGN
Cash 84.53M 13.99B AMGN
Current Ratio 4.57 1.37 DNA
Free Cash Flow -95.51M 4.97B AMGN

Relative Price Performance (Last 90 Days)

DNA 1M: -4.1% · 3M: +31.9% AMGN 1M: +8.4% · 3M: +16.9%

Current Technical Phase

DNA

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 46

RSI (14): 46.3 · Price: $9.83

AMGN

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (3.1% over 20 days), RSI 61

RSI (14): 61.3 · Price: $439.97

Fundamentals Snapshot

Metric DNA AMGN
Market Cap — —
Forward P/E -3.4 17.9
Trailing P/E — 27.8
Revenue (TTM) — —
Revenue Growth -0.5% 0.1%
Gross Margin 0.7% 0.7%
Operating Margin -2.8% 0.4%
EPS -5.06 16.10
Dividend Yield — 0.02%

Frequently Asked Questions

Based on our detailed analysis, DNA is currently the stronger investment candidate, winning 1 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.